End-staged joint diseases
Conditions
Interventions
A:basic blood management+EPO preoperative 3 days to postoperative 5 days first time 40000U then 10000U one time*8 days
B:basic blood management+EPO postoperative 5 days, first time 40000U then 10000U one time*5 day
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving total hip arthroplasty/total knee arthroplasty for end-staged joint diseases; 2. Aged from 40-70 years with no limitation of gender; 3. For male, the preoperative Hb should be no more than 130g/L. For female, the preoperative Hb should be no more than 115g/L; 4. Patients who volunteered to participate in clinical trials and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients combined with acute trauma, tumor, severe osteoporosis, other autoimmune diseases and severe muscle contracture deformity around hip/knee; 2. Previous history of neuro-vascular injury, vasculitis and diabetic foot etc; 3. Related thrombosis history, such as pulmonary embolism, thrombosis and deep vein thrombosis in recent three months; 4. Coagulation disorders, bleeding tendency or intraoperative active bleeding; 5. Clear history of iron metabolism disorders; 6. Sever comorbidities in brain cardiovascular system, liver (ALT or AST >2 high limitation of normal value), kidney (BUN >1.5 high limitation of normal value or Cr> 1.5 high limitation of normal value), endocrine, nerve, hematopoietic system or consciousness disorders; 7. Pregnancy or breast-feeding; 8. Allergy to the test drug and human serum albumin, severe allergies, drug or alcohol depedence; 9. Participate in other clinical trials in recent three months; 10. The surgeons believe the patients not suitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HB;expenditure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hit;RET;perioperative transfusion;Transfusion rate;anemia rate;Range of motion;ESR;CRP;IL6; | — |
Countries
China
Contacts
Public ContactZhou Zong-ke
West China Hospital, Sichuan University
Outcome results
None listed